Latest Placebo-controlled study Stories
MOMENCE, Ill., June 17, 2014 /PRNewswire/ -- FutureCeuticals, Inc.
Previously released interim results from the trial showed positive safety and efficacy; 300 patients with moderate to severe disease were enrolled in the study PETACH TIKVA, Israel,
- Pooled Efficacy Analyses from Phase 3 ASCEND and CAPACITY Studies Presented at 2014 American Thoracic Society Meeting - SAN DIEGO, May 20, 2014 /PRNewswire/ -- InterMune, Inc.
Results from Boehringer Ingelheim, InterMune and IPFnet clinical trials discussed CHICAGO, May 18, 2014 /PRNewswire-USNewswire/ -- WHO: The Pulmonary Fibrosis
TORONTO, May 15, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient in a Phase 2
CLEVELAND, May 6, 2014 /PRNewswire-USNewswire/ -- Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a late-breaking
TOKYO and SAN FRANCISCO, May 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced that the U.S.
Can a Simple Pill Truly Reshape Your Body in 30 Days? SAN DIEGO, May 1, 2014 /PRNewswire/ -- When people walked into the huge exhibit hall for the Experimental Biology conference that
LEXINGTON, Massachusetts, April 30, 2014 /PRNewswire/ -- - OPUS-2, a Phase 3 placebo-controlled study of lifitegrast 5.0%; results presented at
TOKYO, April 16, 2014 /PRNewswire/ -- Ajinomoto Pharmaceuticals Co., Ltd.
- totally perplexed and mixed up.